Overview

Study to Evaluate the Efficacy and Safety of Oral RP7214, a DHODH Inhibitor, in Patients With Symptomatic Mild COVID-19 Infection.

Status:
Recruiting

Trial end date:
2022-02-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled study of RP7214 in patients with symptomatic mild SARS-CoV-2 infection, having at least one high-risk feature (e.g., age > 60 years, hypertension, diabetes mellitus, chronic lung disease, chronic kidney disease, liver disease, cerebrovascular disease, obesity, cancer) for developing severe Covid-19 illness.

Phase:

Phase 2

Details

Lead Sponsor:

Rhizen Pharmaceuticals SA

Collaborator:

Incozen Therapeutics Pvt Ltd